{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:19Z","timestamp":1790375959728,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11899-020-00561-w","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T11:04:01Z","timestamp":1580727841000},"page":"9-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma"],"prefix":"10.1007","volume":"15","author":[{"given":"Lauren","family":"Shea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"issue":"11","key":"561_CR1","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211\u20137.","journal-title":"Ann Oncol"},{"issue":"10","key":"561_CR2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570\u20137.","journal-title":"Blood."},{"issue":"25","key":"561_CR3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"18","key":"561_CR4","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood."},{"issue":"10168","key":"561_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"\u2022\u2022 Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340 This landmark randomized phase III trial showed a survival advantage for BV+CHP over CHOP chemotherapy in frontline treatment of CD30-expressing PTCL.","journal-title":"Lancet."},{"issue":"16","key":"561_CR6","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970\u20136.","journal-title":"J Clin Oncol"},{"key":"561_CR7","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood.V130.Suppl_1.821.821","volume":"130","author":"N Mehta-Shah","year":"2017","unstructured":"Mehta-Shah N, Teja S, Tao Y, Cashen AF, Beaven A, Alpdogan O, et al. Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis. Blood. 2017;130:4597.","journal-title":"Blood."},{"issue":"9","key":"561_CR8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O'Connor","year":"2011","unstructured":"O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"561_CR9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol"},{"issue":"23","key":"561_CR10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"561_CR11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778\u201384.","journal-title":"Nat Biotechnol"},{"issue":"20","key":"561_CR12","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063\u201370.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"561_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.85","volume":"7","author":"CA van der Weyden","year":"2017","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603.","journal-title":"Blood Cancer J"},{"issue":"5878","key":"561_CR14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/299065a0","volume":"299","author":"U Schwab","year":"1982","unstructured":"Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin\u2019s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65\u20137.","journal-title":"Nature."},{"issue":"3","key":"561_CR15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","volume":"68","author":"H Durkop","year":"1992","unstructured":"Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin\u2019s disease. Cell. 1992;68(3):421\u20137.","journal-title":"Cell."},{"issue":"19","key":"561_CR16","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","volume":"124","author":"C Bossard","year":"2014","unstructured":"Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983\u20136.","journal-title":"Blood."},{"issue":"32","key":"561_CR17","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759\u201365.","journal-title":"J Clin Oncol"},{"issue":"32","key":"561_CR18","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","volume":"33","author":"YH Kim","year":"2015","unstructured":"Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750\u20138.","journal-title":"J Clin Oncol"},{"issue":"20","key":"561_CR19","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"\u2022 Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095\u2013100 This phase II study established the activity of single-agent BV in R\/R PTCL.","journal-title":"Blood."},{"key":"561_CR20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hon.149_2631","volume":"37","author":"D. Jagadeesh","year":"2019","unstructured":"Jagadeesh D, Horwitz SM, Bartlett NL, Advani RH, Jacobsen ED, Duvic M, et al. Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas. J Clin Oncol. 2019;37(15).","journal-title":"Hematological Oncology"},{"issue":"2","key":"561_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1309\/HEFL7KC435KFWEX8","volume":"119","author":"J Juco","year":"2003","unstructured":"Juco J, Holden JT, Mann KP, Kelley LG, Li S. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. Am J Clin Pathol. 2003;119(2):205\u201312.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"561_CR22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3960\/jslrt.17023","volume":"57","author":"N Tsuyama","year":"2017","unstructured":"Tsuyama N, Sakamoto K, Sakata S, Dobashi A, Takeuchi K. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017;57(3):120\u201342.","journal-title":"J Clin Exp Hematop"},{"issue":"8","key":"561_CR23","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81\u20132.","journal-title":"Haematologica."},{"issue":"2","key":"561_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","volume":"58","author":"K Karube","year":"2008","unstructured":"Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int. 2008;58(2):89\u201397.","journal-title":"Pathol Int"},{"issue":"2","key":"561_CR25","first-page":"509","volume":"146","author":"A Murray","year":"1995","unstructured":"Murray A, Cuevas EC, Jones DB, Wright DH. Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma. Am J Pathol. 1995;146(2):509\u201319.","journal-title":"Am J Pathol"},{"issue":"4","key":"561_CR26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/PAS.0b013e31824433d8","volume":"36","author":"T Pongpruttipan","year":"2012","unstructured":"Pongpruttipan T, Sukpanichnant S, Assanasen T, Wannakrairot P, Boonsakan P, Kanoksil W, et al. Extranodal NK\/T-cell lymphoma, nasal type, includes cases of natural killer cell and alphabeta, gammadelta, and alphabeta\/gammadelta T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012;36(4):481\u201399.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"561_CR27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.5858\/arpa.2014-0079-RS","volume":"139","author":"Y Shi","year":"2015","unstructured":"Shi Y, Wang E. Hepatosplenic T-cell lymphoma: a clinicopathologic review with an emphasis on diagnostic differentiation from other T-cell\/natural killer-cell neoplasms. Arch Pathol Lab Med. 2015;139(9):1173\u201380.","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"561_CR28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.hoc.2016.11.006","volume":"31","author":"MB Sauder","year":"2017","unstructured":"Sauder MB, O'Malley JT, LeBoeuf NR. CD30(+) Lymphoproliferative disorders of the skin. Hematol Oncol Clin North Am. 2017;31(2):317\u201334.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"32","key":"561_CR29","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766\u201373.","journal-title":"J Clin Oncol"},{"issue":"1","key":"561_CR30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","volume":"16","author":"R Talpur","year":"2016","unstructured":"Talpur R, Sui D, Gangar P, Dabaja BS, Duvic M. Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2016;16(1):49\u201356.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"561_CR31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","volume":"119","author":"MF Benner","year":"2012","unstructured":"Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119(7):1643\u20139.","journal-title":"Blood."},{"issue":"4","key":"561_CR32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11899-011-0096-8","volume":"6","author":"M Duvic","year":"2011","unstructured":"Duvic M. CD30+ neoplasms of the skin. Curr Hematol Malig Rep. 2011;6(4):245\u201350.","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"561_CR33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","volume":"90","author":"R Chiarle","year":"1999","unstructured":"Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90(2):157\u201364.","journal-title":"Clin Immunol"},{"issue":"4","key":"561_CR34","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.4049\/jimmunol.172.4.2186","volume":"172","author":"K Matsumoto","year":"2004","unstructured":"Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol. 2004;172(4):2186\u201393.","journal-title":"J Immunol"},{"issue":"19","key":"561_CR35","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","volume":"25","author":"SM Ansell","year":"2007","unstructured":"Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"561_CR36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","volume":"146","author":"A Forero-Torres","year":"2009","unstructured":"Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171\u20139.","journal-title":"Br J Haematol"},{"issue":"5","key":"561_CR37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1021\/bc050201y","volume":"16","author":"MM Sun","year":"2005","unstructured":"Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem. 2005;16(5):1282\u201390.","journal-title":"Bioconjug Chem"},{"issue":"7","key":"561_CR38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/protein\/gzl013","volume":"19","author":"CF McDonagh","year":"2006","unstructured":"McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel. 2006;19(7):299\u2013307.","journal-title":"Protein Eng Des Sel"},{"issue":"1","key":"561_CR39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2141.2008.07146.x","volume":"142","author":"E Oflazoglu","year":"2008","unstructured":"Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol. 2008;142(1):69\u201373.","journal-title":"Br J Haematol"},{"issue":"19","key":"561_CR40","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"\u2022 Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812\u201321 This was the initial phase I study that established 1.8 mg\/kg every three weeks at the maximum tolerated dose of BV.","journal-title":"N Engl J Med"},{"issue":"18","key":"561_CR41","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","volume":"123","author":"MD Gandhi","year":"2014","unstructured":"Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2014;123(18):2895\u20137.","journal-title":"Blood."},{"issue":"1","key":"561_CR42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-014-0036-x","volume":"14","author":"SA Urru","year":"2014","unstructured":"Urru SA, Mariotti E, Carta P, Massidda S, Marcias M, Murru R, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report. Drugs R D. 2014;14(1):9\u201311.","journal-title":"Drugs R D"},{"issue":"18","key":"561_CR43","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"\u2022 Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190\u20136 This phase II study demonstrated durable responses to single-agent BV in relapsed \/ refractory systemic anaplastic large cell lymphoma.","journal-title":"J Clin Oncol"},{"issue":"25","key":"561_CR44","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","volume":"130","author":"B Pro","year":"2017","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709\u201317.","journal-title":"Blood."},{"issue":"28","key":"561_CR45","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137\u201343.","journal-title":"J Clin Oncol"},{"issue":"19","key":"561_CR46","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","volume":"131","author":"MA Fanale","year":"2018","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018;131(19):2120\u20134.","journal-title":"Blood."},{"issue":"10094","key":"561_CR47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"\u2022 Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366 This randomized phase III study demonstrated superior response rates and progression-free survival with BV compared to invesgitator\u2019s choice of standard therapy in CD30-expressing CTCL.","journal-title":"Lancet."},{"issue":"25","key":"561_CR48","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d'Amore","year":"2012","unstructured":"d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"561_CR49","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.bbmt.2015.04.022","volume":"21","author":"M Afable","year":"2015","unstructured":"Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, et al. Hematopoietic progenitor cell harvesting is feasible after treatment with brentuximab vedotin in CD30(+) lymphoma patients who received multiple prior lines of treatment. Biol Blood Marrow Transplant. 2015;21(8):1529\u201331.","journal-title":"Biol Blood Marrow Transplant"},{"key":"561_CR50","doi-asserted-by":"crossref","unstructured":"Savage KJ, Horwitz SM, Advani R, Christensen JH, Domenech ED, Rossi G, et al. An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant. American Society of Hematology Annual Meeting. 2019 (Abstract #464).","DOI":"10.1182\/blood-2019-122781"},{"issue":"9980","key":"561_CR51","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853\u201362.","journal-title":"Lancet."},{"issue":"25","key":"561_CR52","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639\u201342.","journal-title":"Blood."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00561-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-020-00561-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00561-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T03:32:48Z","timestamp":1665718368000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-020-00561-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s11899-020-00561-w","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"3 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"Dr. Mehta-Shah reports institutional research support from Bristol Myers-Squib, Celegene, Seattle Genetics, Genentech\/Roche, Corvus Pharmaceuticals, Verastem Pharmaceuticals, and Innate Pharmaceuticals. She has served as a consultant for Iowa Hakka Kirin. Dr. Shea reports no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}